Construction of a Non-Mutually Exclusive Decision Tree for Medication Recommendation of Chronic Heart Failure

Yongyi Bai1,2, Haishen Yao3, Xuehan Jiang3

  • 1Department of Cardiology, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.

Insights

This study introduces a nonmutually exclusive decision tree to improve heart failure (HF) treatment recommendations. The novel framework helps personalize medication strategies for complex patient cases, enhancing clinical decision support systems.

Area of Science:

  • Cardiology
  • Medical Informatics
  • Computational Biology

Background:

  • Standardized heart failure (HF) treatment guidelines face challenges due to complex patient profiles.
  • Current decision trees may not accommodate patients satisfying multiple, non-exclusive recommendations.
  • Personalized treatment strategies are crucial for managing complicated cardiovascular diseases.

Purpose of the Study:

  • To propose a novel nonmutually exclusive decision tree framework for building recommendation systems.
  • To apply this framework for evidence-based medication recommendations in heart failure (HF).
  • To demonstrate the system's capability in handling complex clinical situations and diverse patient needs.

Main Methods:

  • Constructed a nonmutually exclusive decision tree using knowledge rules from HF clinical guidelines.
  • Defined patient similarity based on shared leaf node allocation patterns.
  • Employed Apriori algorithms to mine frequent medication patterns and performed outcome prognosis analyses.

Main Results:

  • A decision tree with 14 leaf nodes was developed, achieving ~90% guideline adherence.
  • Tested on a large dataset (29,689 patients, 84,705 admissions) for HF treatment recommendations.
  • Identified top patient subgroups accounting for 32.84% of the population; prognosis analysis revealed no single medication pattern benefits all outcomes.

Conclusions:

  • Proposed a methodology for constructing nonmutually exclusive decision trees for medication recommendations in HF.
  • Demonstrated the application of this framework within a clinical decision support system (CDSS).
  • The proposed framework is adaptable for developing CDSS for various complex diseases.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
453
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
58
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
543
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.3K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
518